COLUMBUS试验更新:encorafenib联合binimetinib对比vemurafenib或encorafenib在BRAF V600突变黑色素瘤中的耐受性与总生存里程碑分析
COLUMBUS试验第1部分纳入577例晚期/转移性BRAF V600突变黑色素瘤患者,随机1:1:1接受COMBO450(encorafenib 450mg QD+binimetinib 45mg BID)、ENCO300(encorafenib 300mg QD)或VEM(vemurafenib 960mg BID)。更新分析显示COMBO450组中位OS为33.6个月,对比VEM降低死亡风险39%(HR 0.61,95%CI 0.48-0.79),中位PFS为14.9个月对比VEM的7.3个月(HR 0.51,95%CI 0.39-0.67),长期随访显示持续获益。
要点
- COMBO450组中位OS 33.6个月,VEM组16.9个月,死亡风险降低39%(HR 0.61)。
- 各年度里程碑OS和PFS结果一致,亚组分析均倾向COMBO450优于VEM。
核心结论
- COLUMBUS试验更新分析显示COMBO450在晚期BRAF V600突变黑色素瘤中具有长期PFS和OS获益。
研究设计与样本
- COLUMBUS试验第1部分为随机3期试验,纳入577例晚期/转移性BRAF V600突变黑色素瘤患者,随机1:1:1接受COMBO450、ENCO300或VEM治疗。
主要发现
- COMBO450、ENCO300和VEM组死亡数分别为116、113和138例,中位OS分别为33.6个月(95%CI 24.4-39.2)、23.5个月(95%CI 19.6-33.6)和16.9个月(95%CI 14.0-24.5)。
- COMBO450对比VEM降低死亡风险39%(HR 0.61,95%CI 0.48-0.79)。
- COMBO450、ENCO300和VEM组中位PFS分别为14.9个月(95%CI 11.0-20.2)、9.6个月(95%CI 7.4-14.8)和7.3个月(95%CI 5.6-7.9),COMBO450对比VEM的PFS HR为0.51(95%CI 0.39-0.67)。
- 各年度里程碑OS和PFS结果一致,亚组分析均倾向COMBO450优于VEM。
关键数值与推荐
- COMBO450方案:encorafenib 450mg QD联合binimetinib 45mg BID;VEM方案:vemurafenib 960mg BID;ENCO300方案:encorafenib 300mg QD。
临床怎么用
- 对于晚期BRAF V600突变黑色素瘤患者,COMBO450较vemurafenib单药显著改善长期OS和PFS,支持该联合方案作为治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BRAF/MEK inhibitor combinations are established treatments for BRAF V600-mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS). Here, we report an updated analysis of the COLUMBUS (COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in BRAF mutant Unresectable Skin cancer) trial with long-term follow-up. METHODS: In part 1 of the COLUMBUS trial, 577 patients with advanced/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450 mg of encorafenib QD + 45 mg of binimetinib BID (COMBO450) vs 960 mg of vemurafenib BID (VEM) or 300 mg of encorafenib ENCO QD (ENCO300). An updated analysis was conducted that included PFS, OS, objective response rate, safety and tolerability and analyses of results by prognostic subgroups. RESULTS: At data cutoff, there were 116, 113 and 138 deaths in the COMBO450, ENCO300 and VEM treatment arms, respectively. The median OS was 33.6 months (95% confidence interval [CI], 24.4-39.2) for COMBO450, 23.5 months (95% CI, 19.6-33.6) for ENCO300 and 16.9 months (95% CI, 14.0-24.5) for VEM. Compared with VEM, COMBO450 decreased the risk of death by 39% (hazard ratio [HR], 0.61; 95% CI, 0.48-0.79). The updated median PFS for COMBO450 was 14.9 months (95% CI, 11.0-20.2), ENCO300 was 9.6 months (95% CI, 7.4-14.8) and VEM was 7.3 months (95% CI, 5.6-7.9). PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67). Landmark OS and PFS results show consistent results for each year analysed. Subgroups all favoured COMBO450 vs VEM. CONCLUSIONS: Updated PFS and OS results for COMBO450 from the COLUMBUS trial demonstrate a long-term benefit in patients with advanced BRAF V600-mutated melanoma.
引用
- Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020. PMID: 31901705. doi:10.1016/j.ejca.2019.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。